InMed Pharmaceuticals Inc. - 8-K Filing

InMed Pharmaceuticals reports Q1 fiscal 2027 results and provides update on proposed merger with Mentari Therapeutics (Items: 7.01 Regulation FD Disclosure, 9.01 Financial Statements and Exhibits)

SEC EDGAR ·

Tickers: $INM

Read the full article at SEC EDGAR

More Regulatory news